Decitabine: a historical review of the development of an epigenetic drug

Abbruzzese J, Raber M, Vrijhof W et al (1991) A phase I trial of laboratory derived synergistic chemotherapeutic (sc) combination: 2′ deoxy-5-azacytidine (DAC) and cisplatin (CDDP). Proc Am Assoc Cancer Res 32:204 (abstr 1219)

Abele R, Clavel M, Dodion P, Bruntsch U, Gundersen S, Smyth J, Renard J, van Glabbeke M, Pinedo HM (1987) The EORTC early clinical trials group experience with 5-aza-2′-deoxycytidine (NSC 127716) in patients with colorectal, head and neck, renal carcinomas and malignant melanomas. Eur J Cancer 23:1921–1924

Aparicio A, Eads CA, Leong LA et al (2003) Phase I trial of continuous infusion 5-aza-2′-deoxycytidine. Cancer Chemother Pharmacol 51:231–239

Bosch van den J, Lübbert M, Verhoef G (2004) The effects of 5-aza-2′-deoxycytidine (decitabine) on the platelet count in patients with intermediate and high-risk myelodysplastic syndromes. Leuk Res 28:785–790

Bouchard J, Momparler RL (1983) Incorporation of 5-aza-2′-deoxycytidine 5′-triphosphate into DNA. Interactions with mammalian DNA polymerase and DNA methylase. Mol Pharmacol 24:109–114

Chabot G, Bouchard J, Momparler RL (1983) Kinetics of deamination of 5-aza-2′-deoxycytidine and cytosine arabinoside by human liver cytidine deaminase and its inhibition by 3-deazauridine, thymidine, and uracil arabinoside. Biochem Pharmacol 32:1327–1328

Constantinides PG, Taylor SM, Jones PA (1978) Phenotypic conversion of cultured mouse embryo cells by aza pyrimidine nucleosides. Dev Biol 66:57–71

Davies MJ, Jenkins PR, Prouse LSJ et al (1991) Structure of 2′-deoxy-5-azacytidine (decitabine) monohydrate. Acta Crystllogr C47:1418–1420

Egger G, Liang G, Aparicio A et al (2004) Epigenetics in human disease and prospects for epigenetic therapy. Nature 429:457–463

Issa JP, Garcia-Manero G, Giles FJ, Mannari R, Thomas D, Faderl S, Bayar E, Lyons J, Rosenfeld CS, Cortes J, Kantarjian HM (2004) Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoetic malignancies. Blood 103:1635–1640

Jones PA, Taylor SM (1980) Cellular differentiation, cytidine analogs and DNA methylation. Cell 20:85–93

Jones PA, Taylor SM, Mohandas T et al (1982) Cell cycle-specific reactivation of an inactive X-chromosome locus by 5-azadeoxycytidine. Proc Natl Acad Sci U S A 79:1215–1219

Kantarjian HM, O'Brien SM, Keating M, Beran M, Estey E, Giralt S, Kornblau S, Rios MB, de Vos D, Talpaz M (1997) Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukaemia. Leukemia 11:1617–1620

Kantarjian HM, Pinto A (eds) (1997) Workshop on the clinical results with decitabine (5-aza-2′-deoxycytabine) in hematologic malignancies. Leukemia 11(suppl monograph 1)

Kantarjian HM, O'Brien S, Cortes J, Giles FJ, Faderl S, Issa JP, Garcia-Manero G, Rios MB, Shan J, Andreeff M, Keating M, Talpaz M (2003) Results of decitabine (5-aza-2′-deoxycytidine) therapy in 130 patients with chronic myeloid leukaemia. Cancer 98:522–528

Koshy M, Dom L, Bressler L, Molokie R, Lavelle D, Talischy N, Hoffman R, van Overveld W, DeSimone J (2000) 2′-deoxy-5-azacytidine and fetal hemoglobin induction in sickle cell anemia. Blood 96:2379–2384

Lima de M, Ravandi F, Shahjahan M, Andersson B, Couriel D, Donato M, Khouri I, Gajewski J, van Besien K, Champlin R, Giralt S, Kantarjian H (2003) Long-term follow-up of a phase I study of high dose decitabine, busulfan, and cyclophosphamide plus allogenic transplantation for the treatment of patients with leukemias. Cancer 97:1242–1247

Lübbert M, Wijermans P, Kunzmann R, Verhoef G, Bosly A, Ravoet C, Andre M, Ferrant A (2001) Cytogenetic responses in high-risk myelodysplastic syndrome following low dose treatment with the DNA methylation inhibitor 5-aza-2′-deoxycytidine. Br J Haematol 114:349–357

Lübbert M, Daskalakis M, Kunzmann R, Engelhardt M, Guo Y, Wijermans P (2004) Nonclonal neutrophil responses after successful treatment of myalodysplasia with low dose 5-aza-2′-deoxycytidine (decitabine). Leuk Res 28:1267–1271

Meulenbelt-Snijders SJ, Meulenbelt F, Paalman ACA et al (1984) Formulering van 5-aza-2′-deoxycytidine, een experimenteel cytostaticum. Pharm Weekbl 119:1186–1189

Momparler RL (1979) Pharmacology of 5-aza-2′-deoxycytidine. FEBS Symp 1979, Antimetab Biochem Biol Med 57:33–41

Momparler RL, Bouchard J, Onetto N, Rivard GE (1984) 5-Aza-2′-deoxycytidine therapy in patients with acute leukaemia inhibits DNA methylation. Leuk Res 8:181–185

Momparler RL, Rossi M, Bouchard J, Vacaro C, Momparler LF (1984) Kinetic interaction of 5-aza-2-deoxycytidine 5′-monophosphate and its 5′-triphosphate with deoxycytilate deaminase. Mol Pharmacol 25:436–438

Momparler RL, Rivard GE, Gyger M (1985) Clinical trial on 5-aza-2′-deoxycytidine in patients with acute leukaemia. Pharmacol Ther 30:277–286

Momparler RL, Vos de D (eds) (1990) 5-Aza-2′-deoxycytidine. Preclinical and clinical studies. PCH Publications, Haarlem, The Netherlands

Momparler RL, Bouffard DY, Momparler LF et al (1997) Pilot phase I–II study on 5-aza-2′-deoxycytidine (decitabine) in patients with metastaic lung cancer. Anticancer Drugs 8:358–368

Momparler RL, Eliopoulos N, Ayoub J (2000) Evaluation of an inhibitor of DNA methylation, 5-aza-2′-deoxycytidine for the treatment of lung cancer and the future role of gene therapy. Adv Exp Med Biol 465:433–446

Momparler RL, Ayoub J (2001) Potential of 5-aza-2′-deoxycytidine (decitabine) a potent inhibitor of DNA methylation for therapy of advanced non-small cell lung cancer. Lung Cancer 34(Suppl 4):S111–S115

Pliml J, Sorm F (1964) Synthesis of 2′-deoxy-d-ribofuranosyl-5-azacytosine. Coll Czech Chem Commun 29:2576–2577

Pinto A, Attadia V, Di Fiore PP et al (1983) 2′-Deoxy-5-azacytidine induces functional and morphological differentiation of a human erythroleukemic cell line (K562). In: Rich MA (ed) Leukemia review international 1. Marcel Dekker, New York, pp 207–208

Pinto A, Attadia V, Fusco A, Ferrara F, Spada OA, Di Fiore PP (1984) 5-Aza-2′-deoxycytidine induces terminal differentiation of leukemic blasts from patients with acute myeloid leukemias. Blood 64:922–929

Pinto A, Maio M, Attadia V, Zappacosta S, Cimino R (1984) Modulation of HLA-DR antigens expression in human myeloid leukaemic cells by cytarabine and 5-aza-2′-deoxycytidine. Lancet 2:867–868

Pinto A, Attadia V (1986) Leukemia therapy by differentiation inducers: the therapeutic concept of differentiation. Cancer J 1:54

Pinto A (eds) (1993) 5-Aza-2′-deoxycytidine and DNA methyltransferase inhibitors in the http://www.nytimes.com/2005/03/16/nyregion/16ferrer.html treatment of myeloid leukemias and myelodysplastic syndromes: biological aspects and clinical results. Leukemia 7(suppl 1)

Piskala A, Sorm F (1978) Anomeric 4-amino-1-(2-deoxy-d-erythro-pentofuranosyl)-s-triazin-2(1H)-ones (2′-deoxy-5-azacytidine and its α-d anomer). Synthesis of 5-azapyrimidine deoxyribonucleosides via acylglucosyl isocyanates. Nucleic Acid Chem 1:443–449

Piskala A, Synackova M, Tomankova H et al (1978) Direct synthesis of 5-azapyrimidine 2′-deoxyribonucleosides. Hydrolysis of 5-aza-2′-deoxycytidine. Nucleic Acid Res Spec Publ 4:109–113

Pohlmann P, DiLeone LP, Cancella AI et al (2002) Phase II trial of cisplatin plus decitabine, a new DNA hypomethylating agent, in patients with advanced squamous carcinoma of the cervix. Am J Clin Oncol 25:496–501

Ravandi F, Kantarjian H, Cohen A, Davis M, O'Brien S, Anderlini P, Andersson B, Claxton D, Donato M, Gajewski J, Khouri I, Korbling M, Ueno N, deVos D, Champlin R, Giralt S (2001) Decitabine with allogenic peripheral blood stem cell transplantation in the therapy of leukaemia relapse following a prior transplant: results of a phase I study. Bone Marrow Transplant 27:1221–1225

Richel DJ (1990) Experimental therapy in Ara-C sensitive and resistant leukaemia, Ph.D. thesis. University of Leiden. The Netherlands

Richel DJ, Colly LP, Kluin-Nelemans JC, Willemze R (1991) The antileukaemic activity of 5-aza-2′-deoxycytidine (Aza-dC) in patients with relapsed acute leukaemia. Br J Cancer 64:144–148

Rivard GE, Momparler RL, Demers J et al (1981) Phase I study on 5-aza-2′-deoxycytidine in children with acute leukemia. Leuk Res 5:453–462

Ruter B, Wijermans PW, Lübbert M (2004) DNA methylation as a therapeutic target in hematologic disorders: recent results in older patients with myodysplasia and acute myeloid leukaemia. Int J Hematol 80:128–135

Sachs L (1978) The differentiation of myeloid leukaemia cells: new possibilities for therapy. Br J Haematol 40:509–517

Schwartsmann G, Schunemann H, Gorini CN et al (2000) A phase I trial of cisplatin plus decitabine, a new DNA-hypomethylating agent, in patients with advanced solid tumors and a follow-up early phase II evaluation in patients with inoperable non-small cell lung cancer. Invest New Drugs 18:83–91

Sessa C, Ten Bokkel Huinink W, Stoter G, Renard J, Cavalli F (1990) Phase II study of 5-aza-2′-deoxycytidine in advanced ovarian cancer. Eur J Cancer 26:137–138

Sorm F, Vesely J (1968) Effect of 5-aza-2′-deoxycytidine against leukemic and hemopoietic tissues in AKR mice. Neoplasma 15:339–343

Thibault A, Figg WD, Bergan RC et al (1998) A phase II study of 5-aza-2′-deoxycytidine (decitabine) in hormone independent metastatic (D2) prostate cancer. Tumori 84:87–89

van Groeningen CJ, Leyva A, O'Brien AM, Gall HE, Pinedo HM (1986) Phase I and pharmacokinetic study of 5-aza-2′-deoxycytidine (NSC 127716) in cancer patients. Cancer Res 46:4831–4836

Vermorken JB, Tumolo S, Roozendaal KJ, Guastalla JP, Splinter TA, Renard J (1991) 5-Aza-2′-deoxycytidine in advanced or recurrent cancer of the cervix. Eur J Cancer 27:216–217

Wijermans P, Lübbert M, Verhoef G et al (2000) Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol 18:956–962

Willemze R, Stegman APA, Colly LP (1990) The use of 5-aza-2′-deoxycytidine (DAC) in adult patients with acute leukaemia (abstr). Haematologica 76:43